Skip to Content

Avrobio Inc AVRO

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.

One Kendall Square, Building 300, Suite 201
Cambridge, MA, 02139
T +1 617 914-8420
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Distressed
Employees 123